index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
27501,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Kenya,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,150,United States,2005,198.78
27502,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Lesotho,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,1061,United States,2005,1406.03
27503,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Malawi,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,93,United States,2005,123.24
27504,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Mozambique,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,115,United States,2005,152.4
27505,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Rwanda,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,58,United States,2005,76.86
27506,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Tanzania,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,147,United States,2005,194.8
27507,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Uganda,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,127,United States,2005,168.3
27508,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Zambia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,103,United States,2005,136.5
27509,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Zimbabwe,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,251,United States,2005,332.62
27510,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Cuba,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,28443,United States,2005,37692.58
27511,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Guyana,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,113,United States,2005,149.75
27512,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Honduras,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,386,United States,2005,511.53
27513,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Bolivia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,246,United States,2005,326
27514,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Haiti,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,105,United States,2005,139.15
27515,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Nicaragua,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,646,United States,2005,856.08
27516,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Afghanistan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,47,United States,2005,62.28
27517,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Djibouti,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,90,United States,2005,119.27
27518,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Pakistan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,192,United States,2005,254.44
27519,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Somalia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,39,United States,2005,51.68
27520,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Sudan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,266,United States,2005,352.5
27521,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Yemen,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,160,United States,2005,212.03
27522,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Armenia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,685,United States,2005,907.76
27523,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Azerbaijan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,95,United States,2005,125.89
27524,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Georgia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,429,United States,2005,568.51
27525,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Kyrgyzstan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,215,United States,2005,284.92
27526,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Tajikistan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,80,United States,2005,106.02
27527,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Uzbekistan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,122,United States,2005,161.67
27528,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Moldova,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,4497,United States,2005,5959.41
27529,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Ukraine,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,12161,United States,2005,16115.72
27530,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Indonesia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,302,United States,2005,400.21
27531,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,South Korea,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,363,United States,2005,481.05
27532,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Sri Lanka,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,1303,United States,2005,1726.73
27533,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Timor-Leste,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,161,United States,2005,213.36
27534,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Bangladesh,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,209,United States,2005,276.97
27535,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Bhutan,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,175,United States,2005,231.91
27536,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,India,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,201,United States,2005,266.36
27537,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Myanmar,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,137,United States,2005,181.55
27538,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Nepal,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,215,United States,2005,284.92
27539,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Cambodia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,44,United States,2005,58.31
27540,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Kiribati,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,111,United States,2005,147.1
27541,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Lao,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,132,United States,2005,174.93
27542,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Mongolia,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,274,United States,2005,363.1
27543,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Papua New Guinea,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,84,United States,2005,111.32
27544,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Solomon Islands,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,444,United States,2005,588.39
27545,Health and economic impact of rotavirus vaccination in GAVI-eligible countries,"ABSTRACT: BACKGROUND: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. METHODS: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. RESULTS: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 52% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. CONCLUSIONS: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.",2010-99-06304,20470426,BMC Public Health,Kerry McBrien,2010,10 / 1,253,No,20470426,"Kerry McBrien; Health and economic impact of rotavirus vaccination in GAVI-eligible countries, BMC Public Health, 2010-May-14; 10(1):1471-2458; 253",DALY,Viet Nam,Not Stated,Immunization,Rotavirus vaccination program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,799,United States,2005,1058.83
27546,"Cost-effectiveness implications of GP intervention to promote physical activity: evidence from Perth, Australia","ABSTRACT: BACKGROUND: Physical inactivity is a major risk factor for many chronic diseases including diabetes, cardiovascular diseases and some cancers. It is estimated that, in Australia, physical inactivity contributes to 13,500 annual deaths and incurs an annual cost of AU$ 21 billion to the health care system. The cost of physical inactivity to the Western Australian (WA) economy is estimated to be about AU$ 2.1 billion. Increased burden of physical inactivity has motivated health professionals to seek cost effective intervention to promote physical activity. One such strategy is encouraging general practitioners (GPs) to advocate physical activity to the patients who are at high risk of developing chronic diseases associated with physical inactivity. This study intends to investigate the cost-effectiveness of a subsidy program for GP advice to promote physical activity. Methodology: The percentage of population that could potentially move from insufficiently active to sufficiently active, on GP advice was drawn from the Western Australian (WA) Premier's Physical Activity Taskforce (PATF) survey in 2006. Population impact fractions (PIF) for diseases attributable to physical inactivity together with disability adjusted life years (DALYs) and health care expenditure were used to estimate the net cost of intervention for varying subsidies. Cost-effectiveness of subsidy programs were evaluated in terms of cost per DALY saved at different compliance rates. RESULTS: With a 50% adherence to GP advice, an annual health care cost of AU$ 24 million could be potentially saved to the WA economy. A DALY can be saved at a cost of AU $ 11,000 with a AU$ 25 subsidy at a 50% compliance rate. Cost effectiveness of such a subsidy program decreases at higher subsidy and lower compliance rates. CONCLUSION: Implementing a subsidy for GP advice could potentially reduce the burden of physical inactivity. However, the cost-effectiveness of a subsidy program for GP advice depends on the percentage of population who comply with GP advice.",2010-99-06310,20462457,Cost Eff Resour Alloc,Kerry McBrien,2010,8 / 1,10,Yes,20462457,"Kerry McBrien; Cost-effectiveness implications of GP intervention to promote physical activity: evidence from Perth, Australia, Cost Eff Resour Alloc, 2010-May-13; 8(1):1478-7547; 10",DALY,Australia,Not Stated,Health Education or Behavior,Subsidy for General practtitioner (GP) advice to promote physical activity vs. None,High risk of developing chronic diseases associated with physical inactivity,Not Stated,12 Years,"Female, Male",Full,Not Stated / None,Not Stated,Not Stated,10775,Australia,2003,9887.28
27547,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Voluntary counseling and testing (VCT) centers for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1047,India,2005,31.54
27548,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Prevention of parent to child transmission (PPTCT) clinics for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,946,India,2005,28.5
27549,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Sexually transmitted infection (STI) clinics for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1306,India,2005,39.35
27550,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Blood banks for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,170,India,2005,5.12
27551,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Women sex worker (SW) programs for HIV prevention vs. None,High risk of HIV,Not Stated,19 Years,Female,Full,,3.00,3.00,1567,India,2005,47.21
27552,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Men who have sex with men (MSM) programs for HIV prevention vs. None,men who have sex with men,Not Stated,19 Years,Male,Full,,3.00,3.00,406,India,2005,12.23
27553,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Trucker programs for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2924,India,2005,88.09
27554,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Composite programs for HIV prevention vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,5733,India,2005,172.72
27555,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Workplace programs for HIV prevention vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,13031,India,2005,392.6
27556,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Migrant Labourer Program for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,3502,India,2005,105.51
27557,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Street children programs for HIV prevention vs. None,High risk of HIV,18 Years,6 Years,"Female, Male",Full,,3.00,3.00,6934,India,2005,208.91
27558,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Prisoner programs for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,12904,India,2005,388.77
27559,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care","State-wide information, education and communication (IEC) programs for the general public for HIV prevention vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,17214,India,2005,518.62
27560,Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India,"BACKGROUND: Information on cost-effectiveness of the range of HIV prevention interventions is a useful contributor to decisions on the best use of resources to prevent HIV. We conducted this assessment for the state of Andhra Pradesh that has the highest HIV burden in India. METHODS: Based on data from a representative sample of 128 public-funded HIV prevention programs of 14 types in Andhra Pradesh, we have recently reported the number of HIV infections averted by each type of HIV prevention intervention and their cost. Using estimates of the age of onset of HIV infection, we used standard methods to calculate the cost per Disability Adjusted Life Year (DALY) saved as a measure of cost-effectiveness of each type of HIV prevention intervention. RESULTS: The point estimates of the cost per DALY saved were less than US $50 for blood banks, men who have sex with men programmes, voluntary counselling and testing centres, prevention of parent to child transmission clinics, sexually transmitted infection clinics, and women sex worker programmes; between US $50 and 100 for truckers and migrant labourer programmes; more than US $100 and up to US $410 for composite, street children, condom promotion, prisoners and workplace programmes and mass media campaign for the general public. The uncertainty range around these estimates was very wide for several interventions, with the ratio of the high to the low estimates infinite for five interventions. CONCLUSIONS: The point estimates for the cost per DALY saved from the averted HIV infections for all interventions was much lower than the per capita gross domestic product in this Indian state. While these indicative cost-effectiveness estimates can inform HIV control planning currently, the wide uncertainty range around estimates for several interventions suggest the need for more firm data for estimating cost-effectiveness of HIV prevention interventions in India.",2010-99-06313,20459755,BMC Health Serv Res,Kerry McBrien,2010,10 /,117,Yes,20459755,"Kerry McBrien; Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India, BMC Health Serv Res, 2010; 10():1472-6963; 117",DALY,India,Not Stated,"Care Delivery, Health Education or Behavior, Maternal / Neonatal / Reproductive Care",Condom promotion program for HIV prevention vs. None,High risk of HIV,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,10942,India,2005,329.66
27561,Drinking water fluoridation in South East Queensland: a cost-effectiveness evaluation,"OBJECTIVE: The aim of this study is to examine cost-effectiveness of fluoridation of drinking water supplies for Brisbane and South East Queensland. The benefits conveyed are expressed in reduced costs of dental treatment and years of life with dental caries as a disability. METHODS: The analysis utilises a developed life table modelling initial cohort of 36,322 newborns, which when applied to the target population equals to 181,925 persons in the age group 2-100 years, 338,617 persons in the age group 7-100 years and 390,524 persons in the age group 12-100 years respectively. The analysis was conducted using a real discount rate of 3%. Sensitivity analyses investigated the effects of varying the parameters such as: discount rate, costs of dental treatment and costs of fluoridation plant. Uncertainty analysis was also conducted on costs and the measure of ratio of decayed, missing, filled teeth surfaces in deciduous dentition between the cities of Brisbane (non-fluoridated) and Townsville (fluoridated). RESULTS: If fluoridation was implemented there would be a total saving of $10,437.43 (95% CI 6,406.50- 14,035.35) disability-adjusted life years (DALYs) and AU$ 665,686,529 (95% CI -$973,573,625- $381,322,176). This result is both desirable and dominant as more DALYs are saved along with significant cost savings. CONCLUSION: Fluoridation remains still a very cost-effective measure for reducing dental decay.",2010-99-06368,20406153,Health Promot J Austr,Kerry McBrien,2010,21 / 1,51-6,No,20406153,"Kerry McBrien; Drinking water fluoridation in South East Queensland: a cost-effectiveness evaluation, Health Promot J Austr, 2010-Apr; 21(1):1036-1073; 51-6",DALY,Australia,Not Stated,Environmental,Drinking water fluoridation for prevention of dental complications vs. None,Not Stated,18 Years,6 Years,"Female, Male",Full,,3.00,3.00,-63811.4,Australia,2003,-58554.16
27562,Cost-effectiveness of volumetric alcohol taxation in Australia,"OBJECTIVE: To estimate the potential health benefits and cost savings of an alcohol tax rate that applies equally to all alcoholic beverages based on their alcohol content (volumetric tax) and to compare the cost savings with the cost of implementation. DESIGN AND SETTING: Mathematical modelling of three scenarios of volumetric alcohol taxation for the population of Australia: (i) no change in deadweight loss, (ii) no change in tax revenue, and (iii) all alcoholic beverages taxed at the same rate as spirits. MAIN OUTCOME MEASURES: Estimated change in alcohol consumption, tax revenue and health benefit. RESULTS: The estimated cost of changing to a volumetric tax rate is $18 million. A volumetric tax that is deadweight loss-neutral would increase the cost of beer and wine and reduce the cost of spirits, resulting in an estimated annual increase in taxation revenue of $492 million and a 2.77% reduction in annual consumption of pure alcohol. The estimated net health gain would be 21 000 disability-adjusted life-years (DALYs), with potential cost offsets of $110 million per annum. A tax revenue-neutral scenario would result in an 0.05% decrease in consumption, and a tax on all alcohol at a spirits rate would reduce consumption by 23.85% and increase revenue by $309 million. All volumetric tax scenarios would provide greater health benefits and cost savings to the health sector than the existing taxation system, based on current understandings of alcohol-related health effects. CONCLUSIONS: An equalized volumetric tax that would reduce beer and wine consumption while increasing the consumption of spirits would need to be approached with caution. Further research is required to examine whether alcohol-related health effects vary by type of alcoholic beverage independent of the amount of alcohol consumed to provide a strong evidence platform for alcohol taxation policies.",2010-99-06373,20402606,Med J Aust,Kerry McBrien,2010,192 / 8,439-43,No,20402606,"Kerry McBrien; Cost-effectiveness of volumetric alcohol taxation in Australia, Med J Aust, 2010-Apr-19; 192(8):0025-729X; 439-43",DALY,Australia,Not Stated,Legislation / Regulation,Volumetric tax rate on all alcoholic beverages vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-5210.48,Australia,2003,-4781.2
27563,"Quantitative Microbial Risk Analysis to evaluate health effects of interventions in the urban water system of Accra, Ghana","A quantitative microbial risk assessment was applied to evaluate the microbial risks of the Accra Urban Water System (AUWS). The exposure assessment was based on the count of indicator organisms in waste water from open roadside drains and in water and sand samples from the beach. The predicted total disease burden generated in a representative catchment of the AUWS (Odaw Catchment) was 36,329 Disability Adjusted Life Years (DALYs) per year, of which 12 and 88% are caused by, respectively, shortcomings in the water supply system and inappropriate sanitation. The DALYs per person per year were above the WHO reference value. The open roadside drain had the highest contribution to the disease burden. Of four possible interventions evaluated for health risk reduction, the highest efficiency in terms of DALYs averted per euro invested would be achieved by providing covers for the open roadside drains.",2010-XX-05954,20375471,J Water Health,Kerry McBrien,2010,8 / 3,417-30,No,20375471,"Kerry McBrien; Quantitative Microbial Risk Analysis to evaluate health effects of interventions in the urban water system of Accra, Ghana, J Water Health, 2010-Sep; 8(3):1477-8920; 417-30",DALY,Ghana,Not Stated,Environmental,Sewage network and sanitation facilities vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,742,United States,2008,891.94
27564,"Quantitative Microbial Risk Analysis to evaluate health effects of interventions in the urban water system of Accra, Ghana","A quantitative microbial risk assessment was applied to evaluate the microbial risks of the Accra Urban Water System (AUWS). The exposure assessment was based on the count of indicator organisms in waste water from open roadside drains and in water and sand samples from the beach. The predicted total disease burden generated in a representative catchment of the AUWS (Odaw Catchment) was 36,329 Disability Adjusted Life Years (DALYs) per year, of which 12 and 88% are caused by, respectively, shortcomings in the water supply system and inappropriate sanitation. The DALYs per person per year were above the WHO reference value. The open roadside drain had the highest contribution to the disease burden. Of four possible interventions evaluated for health risk reduction, the highest efficiency in terms of DALYs averted per euro invested would be achieved by providing covers for the open roadside drains.",2010-XX-05954,20375471,J Water Health,Kerry McBrien,2010,8 / 3,417-30,No,20375471,"Kerry McBrien; Quantitative Microbial Risk Analysis to evaluate health effects of interventions in the urban water system of Accra, Ghana, J Water Health, 2010-Sep; 8(3):1477-8920; 417-30",DALY,Ghana,Not Stated,Environmental,Sewage network and sanitation facilities combined with treatment plant vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,1105,United States,2008,1328.3
27565,Potential epidemiological and economical impact of two rotavirus vaccines in Colombia,"A complete economic study was carried out to assess the economical impact of two rotavirus vaccine in Colombia. A Markov decision model was built to assess the health outcomes from birth to 24 months of age for three hypothetical cohorts: one unvaccinated, one vaccinated with 2 doses of Rotarix and the third, with 3 doses of Rotateq. Without vaccination, the annual number of medical visits by diarrhea in children under 2 years would be 1,293,159 cases, with 105,378 medical visits and 470 deaths (IC95% 295-560) related to rotavirus. Without vaccination, rotavirus disease would cost around USD$8 millions including direct and indirect costs. Assuming a cost per dose of USD$7.5, average cost-effectiveness ratio would be USD$663/DALY with Rotarix and USD$1391 with Rotateq. When price per dose falls below USD$7 both vaccines yield a similar average cost-effectiveness ratio (USD$1063/DALY). Incremental cost-effectiveness ratio of Rotateq versus Rotarix was USD$7787/DALY. Cost-effectiveness ratio was influenced mainly by vaccine cost and cost per case hospitalized. Other programmatic aspects such as number of doses to be applied, likelihood of completing vaccination schedule with shorter versus longer schedules, and storage space within the chain cold should be considered to make decisions on which vaccine should be introduced. In conclusion, vaccinating against rotavirus in Colombia with either vaccine would be very cost effective. If cost per vaccinated children falls below USD$3 per dose vaccination would be cost saving.",2010-01-01537,20347057,Vaccine,Fernando de La Hoz,2010,28 / 22,3856-64,Yes,20347057,"Fernando de La Hoz; Nelson Alvis; Javier Narv?ez; Natalia Cediel; Oscar Gamboa; Martha Velandia; Javier Narvaez; Juliana Lustosa Torres; Rosangela Correa Dias; Fabiane Ribeiro Ferreira; James Macinko; Maria Fernanda Lima-Costa; Potential epidemiological and economical impact of two rotavirus vaccines in Colombia, Vaccine, ; 28(22):1873-2518; 3856-64",DALY,Colombia,Not Stated,Immunization,Rotarix rotavirus vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,663,United States,2003,932.56
27566,Potential epidemiological and economical impact of two rotavirus vaccines in Colombia,"A complete economic study was carried out to assess the economical impact of two rotavirus vaccine in Colombia. A Markov decision model was built to assess the health outcomes from birth to 24 months of age for three hypothetical cohorts: one unvaccinated, one vaccinated with 2 doses of Rotarix and the third, with 3 doses of Rotateq. Without vaccination, the annual number of medical visits by diarrhea in children under 2 years would be 1,293,159 cases, with 105,378 medical visits and 470 deaths (IC95% 295-560) related to rotavirus. Without vaccination, rotavirus disease would cost around USD$8 millions including direct and indirect costs. Assuming a cost per dose of USD$7.5, average cost-effectiveness ratio would be USD$663/DALY with Rotarix and USD$1391 with Rotateq. When price per dose falls below USD$7 both vaccines yield a similar average cost-effectiveness ratio (USD$1063/DALY). Incremental cost-effectiveness ratio of Rotateq versus Rotarix was USD$7787/DALY. Cost-effectiveness ratio was influenced mainly by vaccine cost and cost per case hospitalized. Other programmatic aspects such as number of doses to be applied, likelihood of completing vaccination schedule with shorter versus longer schedules, and storage space within the chain cold should be considered to make decisions on which vaccine should be introduced. In conclusion, vaccinating against rotavirus in Colombia with either vaccine would be very cost effective. If cost per vaccinated children falls below USD$3 per dose vaccination would be cost saving.",2010-01-01537,20347057,Vaccine,Fernando de La Hoz,2010,28 / 22,3856-64,Yes,20347057,"Fernando de La Hoz; Nelson Alvis; Javier Narv?ez; Natalia Cediel; Oscar Gamboa; Martha Velandia; Javier Narvaez; Juliana Lustosa Torres; Rosangela Correa Dias; Fabiane Ribeiro Ferreira; James Macinko; Maria Fernanda Lima-Costa; Potential epidemiological and economical impact of two rotavirus vaccines in Colombia, Vaccine, ; 28(22):1873-2518; 3856-64",DALY,Colombia,Not Stated,Immunization,Rotateq rotavirus vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,1391,United States,2003,1956.55
27567,Potential epidemiological and economical impact of two rotavirus vaccines in Colombia,"A complete economic study was carried out to assess the economical impact of two rotavirus vaccine in Colombia. A Markov decision model was built to assess the health outcomes from birth to 24 months of age for three hypothetical cohorts: one unvaccinated, one vaccinated with 2 doses of Rotarix and the third, with 3 doses of Rotateq. Without vaccination, the annual number of medical visits by diarrhea in children under 2 years would be 1,293,159 cases, with 105,378 medical visits and 470 deaths (IC95% 295-560) related to rotavirus. Without vaccination, rotavirus disease would cost around USD$8 millions including direct and indirect costs. Assuming a cost per dose of USD$7.5, average cost-effectiveness ratio would be USD$663/DALY with Rotarix and USD$1391 with Rotateq. When price per dose falls below USD$7 both vaccines yield a similar average cost-effectiveness ratio (USD$1063/DALY). Incremental cost-effectiveness ratio of Rotateq versus Rotarix was USD$7787/DALY. Cost-effectiveness ratio was influenced mainly by vaccine cost and cost per case hospitalized. Other programmatic aspects such as number of doses to be applied, likelihood of completing vaccination schedule with shorter versus longer schedules, and storage space within the chain cold should be considered to make decisions on which vaccine should be introduced. In conclusion, vaccinating against rotavirus in Colombia with either vaccine would be very cost effective. If cost per vaccinated children falls below USD$3 per dose vaccination would be cost saving.",2010-01-01537,20347057,Vaccine,Fernando de La Hoz,2010,28 / 22,3856-64,Yes,20347057,"Fernando de La Hoz; Nelson Alvis; Javier Narv?ez; Natalia Cediel; Oscar Gamboa; Martha Velandia; Javier Narvaez; Juliana Lustosa Torres; Rosangela Correa Dias; Fabiane Ribeiro Ferreira; James Macinko; Maria Fernanda Lima-Costa; Potential epidemiological and economical impact of two rotavirus vaccines in Colombia, Vaccine, ; 28(22):1873-2518; 3856-64",DALY,Colombia,Not Stated,Immunization,Rotateq rotavirus vaccination vs. Rotarix rotavirus vaccination,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,7787,United States,2003,10953.05
27568,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Nigeria,Not Stated,Environmental,Biocontrol of maize intended for human consumption to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,13.8,United States,2009,16.65
27569,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Nigeria,Not Stated,Environmental,Biocontrol of all maize grown to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,5.1,United States,2009,6.15
27570,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Guinea,Not Stated,Environmental,Postharvest intervention package in Guinean groundnuts harvested for human consumption to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,0.82,United States,2009,0.99
27571,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Guinea,Not Stated,Environmental,Postharvest intervention package in all Guinea groudnuts harvested to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,0.21,United States,2009,0.25
27572,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Nigeria,Not Stated,Environmental,Biocontrol of maize intended for human consumption to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,24.8,United States,2009,29.92
27573,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Nigeria,Not Stated,Environmental,Biocontrol of all maize grown to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,9.8,United States,2009,11.82
27574,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Guinea,Not Stated,Environmental,Postharvest intervention package in Guinean groundnuts harvested for human consumption to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2.08,United States,2009,2.51
27575,Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions,"Advances in health economics have proven useful in evaluating the cost-effectiveness of interventions, where the benefit usually takes the form of improved health outcomes rather than market outcomes. The paper performs health-based cost-effectiveness analyses of two potential aflatoxin control strategies in Africa: (1) pre-harvest biocontrol, using atoxigenic strains of Aspergillus flavus competitively to exclude toxigenic strains from colonizing maize in Nigeria; and (2) post-harvest interventions in a package to reduce aflatoxin accumulation in groundnuts in Guinea. It is described how health benefits gained from each intervention, in terms of fewer aflatoxin-induced hepatocellular carcinoma cases, can be compared with the costs of implementing the interventions. It is found that both interventions would be extremely cost-effective if applied widely in African agriculture. That is, the monetized value of lives saved and quality of life gained by reducing aflatoxin-induced hepatocellular carcinoma far exceeds the cost of either biocontrol or the post-harvest intervention package to achieve those health benefits. The estimated cost-effectiveness ratio (CER; gross domestic product multiplied by disability-adjusted life years saved per unit cost) for biocontrol in Nigerian maize ranged from 5.10 to 24.8; while the estimated CER for the post-harvest intervention package in Guinean groundnuts ranged from 0.21 to 2.08. Any intervention with a CER > 1 is considered by the World Health Organization (WHO) to be 'very cost-effective', while an intervention with a CER > 0.33 is considered 'cost-effective'. Aside from cost-effectiveness, public health interventions must be readily accepted by the public, and must have financial and infrastructural support to be feasible in the parts of the world where they are most needed.",2010-99-06417,20234965,Food Addit Contam Part A Chem Anal Control Expo Risk Assess,Kerry McBrien,2010,27 / 4,496-509,No,20234965,"Kerry McBrien; Health economic impacts and cost-effectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions, Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2010-Apr; 27(4):1944-0057; 496-509",DALY,Guinea,Not Stated,Environmental,Postharvest intervention package in all Guinea groudnuts harvested to reduce aflatoxin-induced hepatocellular carcinoma cases vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,0.55,United States,2009,0.66
27576,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other",Pre-diabetes screen screen plus diet and exercise to prevent or slow the onset of diabetes vs. Standard/Usual Care,High risk factors for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,23000,Australia,2003,21105.1
27577,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other",Pre-diabetes screen plus exercise to prevent or slow the onset of diabetes vs. Standard/Usual Care,High Risk for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,30000,Australia,2003,27528.39
27578,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other",Pre-diabetes screen plus diet to prevent or slow the onset of diabetes vs. Standard/Usual Care,High risk for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,38000,Australia,2003,34869.29
27579,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other",Pre-diabetes screen plus Acarbose to prevent or slow the onset of diabetes vs. Standard/Usual Care,High risk for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,37000,Australia,2003,33951.68
27580,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other",Pre-diabetes screen plus Metformin to prevent or slow the onset of diabetes vs. Standard/Usual Care,High risk for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,22000,Australia,2003,20187.48
27581,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other",Pre-diabetes screen plus Orlistat to prevent or slow the onset of diabetes vs. Standard/Usual Care,High risk for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,100000,Australia,2003,91761.29
27582,Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care,"AIMS/HYPOTHESIS: This study aims to evaluate the cost-effectiveness of a screening programme for pre-diabetes, which was followed up by treatment with pharmaceutical interventions (acarbose, metformin, orlistat) or lifestyle interventions (diet, exercise, diet and exercise) in order to prevent or slow the onset of diabetes in those at high risk. METHODS: To approximate the experience of individuals with pre-diabetes in the Australian population, we used a microsimulation approach, following patient progression through diabetes, cardiovascular disease and renal failure. The model compares costs and disability-adjusted life years lived in people identified through an opportunistic screening programme for each intervention compared with a 'do nothing' scenario, which is representative of current practice. It is assumed that the effect of a lifestyle change will decay by 10% per year, while the effect of a pharmaceutical intervention remains constant throughout use. RESULTS: The most cost-effective intervention options are diet and exercise combined, with a cost-effectiveness ratio of AUD 22,500 per disability-adjusted life year (DALY) averted, and metformin with a cost-effectiveness ratio of AUD 21,500 per DALY averted. The incremental addition of one intervention to the other is not cost-effective. CONCLUSIONS/INTERPRETATION: Screening for pre-diabetes followed by diet and exercise, or metformin treatment is cost-effective and should be considered for incorporation into current practice. The number of dietitians and exercise physiologists needed to deliver such lifestyle change interventions will need to be increased to appropriately support the intervention.",2010-99-06096,20135088,Diabetologia,Kerry McBrien,2010,53 / 5,875-81,No,20135088,"Kerry McBrien; Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care, Diabetologia, 2010-May; 53(5):0012-186X; 875-81",DALY,Australia,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening, Other","Pre-diabetes screen plus Metformin, diet and exercise to prevent or slow the onset of diabetes vs. Standard/Usual Care",High risk for pre-diabetes,Not Stated,41 Years,"Female, Male",Full,,3.00,3.00,81000,Australia,2003,74326.64
27583,Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?,"This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.",2010-99-06126,20109593,Vaccine,Kerry McBrien,2010,28 / 14,2624-35,Yes,20109593,"Kerry McBrien; Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?, Vaccine, 2010-Mar-19; 28(14):1873-2518; 2624-35",DALY,Netherlands,Not Stated,Immunization,Rotarix rotavirus vaccine vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,4.00,1.50,49000,Euro,2006,79027.67
27584,Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?,"This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.",2010-99-06126,20109593,Vaccine,Kerry McBrien,2010,28 / 14,2624-35,Yes,20109593,"Kerry McBrien; Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?, Vaccine, 2010-Mar-19; 28(14):1873-2518; 2624-35",DALY,Netherlands,Not Stated,Immunization,RotaTeq rotavirus vaccination vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,4.00,1.50,54000,Euro,2006,87091.71
27585,"Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: cost-effectiveness, mortality, and morbidity reduction analysis","OBJECTIVE: To compare the cost-effectiveness of community-based distribution of misoprostol for prevention with misoprostol for treatment of postpartum hemorrhage (PPH). METHODS: A Monte Carlo simulation depicted mortality and anemia-related morbidity attributable to PPH among 3 scenarios of 10,000 women delivering at home in rural India: (1) standard management; (2) standard management plus 800microg of sublingual misoprostol for PPH treatment; and (3) standard management plus 600microg of prophylactic oral misoprostol. The model included costs of drugs, birth attendant training, and transport for women who did not respond to misoprostol. RESULTS: Misoprostol lowered mortality by 70% and 81% in scenarios 2 and 3, respectively. Scenarios 2 and 3 raise costs by 6% and 35%, respectively. Incremental cost per disability-adjusted life year (DALY) saved is estimated at $6 and $170, respectively. CONCLUSION: Both interventions were more effective at decreasing mortality and anemia than standard management. The most efficient scale-up plan would focus initially on increasing coverage with the treatment strategy ($6 per DALY).",2010-99-06170,20079493,Int J Gynaecol Obstet,Kerry McBrien,2010,108 / 3,289-94,No,20079493,"Kerry McBrien; Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: cost-effectiveness, mortality, and morbidity reduction analysis, Int J Gynaecol Obstet, 2010-Mar; 108(3):0020-7292; 289-94",DALY,India,Not Stated,Pharmaceutical,Misoprostol treatment vs. None,Not Stated,Not Stated,Not Stated,Female,Full,,Not Stated,3.00,6,United States,2009,7.24
27586,"Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: cost-effectiveness, mortality, and morbidity reduction analysis","OBJECTIVE: To compare the cost-effectiveness of community-based distribution of misoprostol for prevention with misoprostol for treatment of postpartum hemorrhage (PPH). METHODS: A Monte Carlo simulation depicted mortality and anemia-related morbidity attributable to PPH among 3 scenarios of 10,000 women delivering at home in rural India: (1) standard management; (2) standard management plus 800microg of sublingual misoprostol for PPH treatment; and (3) standard management plus 600microg of prophylactic oral misoprostol. The model included costs of drugs, birth attendant training, and transport for women who did not respond to misoprostol. RESULTS: Misoprostol lowered mortality by 70% and 81% in scenarios 2 and 3, respectively. Scenarios 2 and 3 raise costs by 6% and 35%, respectively. Incremental cost per disability-adjusted life year (DALY) saved is estimated at $6 and $170, respectively. CONCLUSION: Both interventions were more effective at decreasing mortality and anemia than standard management. The most efficient scale-up plan would focus initially on increasing coverage with the treatment strategy ($6 per DALY).",2010-99-06170,20079493,Int J Gynaecol Obstet,Kerry McBrien,2010,108 / 3,289-94,No,20079493,"Kerry McBrien; Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: cost-effectiveness, mortality, and morbidity reduction analysis, Int J Gynaecol Obstet, 2010-Mar; 108(3):0020-7292; 289-94",DALY,India,Not Stated,Pharmaceutical,Prophylactic misoprostol vs. Misoprostol (600 micrograms sublingual) for treatment for postpartum hemorrhage,Not Stated,Not Stated,Not Stated,Female,Full,,Not Stated,3.00,170,United States,2009,205.08
27587,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Viet Nam,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Ho Chi Minh City,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,347.78,United States,2008,418.06
27588,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Viet Nam,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Hanoi,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,347.63,United States,2008,417.88
27589,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Viet Nam,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Kien Giang,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,661.21,United States,2008,794.83
27590,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Viet Nam,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Hue,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,850.06,United States,2008,1021.84
27591,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Russia,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Not Stated,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,870,United States,2008,1045.81
27592,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Nicaragua,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Not Stated,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,1827.88,United States,2008,2197.25
27593,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,Kenya,Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,Not Stated,5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,1192.86,United States,2008,1433.91
27594,Cleft lip and palate as a cost-effective health care treatment in the developing world,"BACKGROUND: The considerable number of surgical procedures performed each year, as well as the significant burden of surgical disease globally, have brought surgery into the arena of public health concerns. Several articles have shown the cost-effectiveness of surgical interventions in the developing world. The authors suggest that surgery has an important role in global public health, specifically through international volunteer surgical missions as a vehicle for delivery. METHODS: Eight Operation Smile medical missions from 2008 are analyzed using the disability-adjusted life year (DALY) framework and disability weights from the life tables of the first Disease Control Priorities Project (DCP1). The DCP1 life tables suggest that the entire burden of disease from a cleft lip and palate is incurred within the first 4 years of life. The same group of missions is analyzed using life tables modified by the authors to reflect the disability associated with cleft lip and palate that goes beyond the first 5 years of life. RESULTS: Using the DCP1 life tables, the cost per patient during the eight Operation Smile missions analyzed was $278 and $1827 with an average of $796. Using the life tables modified by the authors, the cost per patient was between $7.36 and $96.04 (average $33.94). CONCLUSIONS: The absence of disability weights for untreated cleft lip and palate after the fifth year of life does not fit with the reality of living with an unrepaired cleft lip or palate. The authors conclude that secondary interventions alleviate disability and should enable an individual to approach a zero residual disability weight.",2010-99-06189,20063097,World J Surg,Kerry McBrien,2010,34 / 3,420-7,No,20063097,"Kerry McBrien; Cleft lip and palate as a cost-effective health care treatment in the developing world, World J Surg, 2010-Mar; 34(3):0364-2313; 420-7",DALY,"Kenya, Nicaragua, Russia, Viet Nam",Not Stated,Surgical,Cleft lip and palate surgery vs. Standard/Usual Care,"Vietnam, Russia, Nicaragua, Kenya",5 Years,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,715.79,United States,2008,860.44
27595,The Cost-effectiveness of Australia's Active After-school Communities Program,"The objective of this study was to assess from a societal perspective the cost-effectiveness of the Active After-school Communities (AASC) program, a key plank of the former Australian Government's obesity prevention program. The intervention was modeled for a 1-year time horizon for Australian primary school children as part of the Assessing Cost-Effectiveness in Obesity (ACE-Obesity) project. Disability-adjusted life year (DALY) benefits (based on calculated effects on BMI post-intervention) and cost-offsets (consequent savings from reductions in obesity-related diseases) were tracked until the cohort reached the age of 100 years or death. The reference year was 2001, and a 3% discount rate was applied. Simulation-modeling techniques were used to present a 95% uncertainty interval around the cost-effectiveness ratio. An assessment of second-stage filter criteria (""equity,"" ""strength of evidence,"" ""acceptability to stakeholders,"" ""feasibility of implementation,"" ""sustainability,"" and ""side-effects"") was undertaken by a stakeholder Working Group to incorporate additional factors that impact on resource allocation decisions. The estimated number of children new to physical activity after-school and therefore receiving the intervention benefit was 69,300. For 1 year, the intervention cost is Australian dollars (AUD) 40.3 million (95% uncertainty interval AUD 28.6 million; AUD 56.2 million), and resulted in an incremental saving of 450 (250; 770) DALYs. The resultant cost-offsets were AUD 3.7 million, producing a net cost per DALY saved of AUD 82,000 (95% uncertainty interval AUD 40,000; AUD 165,000). Although the program has intuitive appeal, it was not cost-effective under base-case modeling assumptions. To improve its cost-effectiveness credentials as an obesity prevention measure, a reduction in costs needs to be coupled with increases in the number of participating children and the amount of physical activity undertaken.",2009-99-05808,19893504,Obesity (Silver Spring),Marjory L Moodie,2009,/,,No,19893504,"Marjory L Moodie; The Cost-effectiveness of Australia's Active After-school Communities Program, Obesity (Silver Spring), 2009-Nov-05; ():1930-7381",DALY,Australia,Not Stated,Health Education or Behavior,Active After-school Communities Program (AASC)--physical activity co-ordinators develop and deliver physical activity program specific to each school vs. None,Previously inactive during after-school hours,11 Years,6 Years,"Female, Male",Full,,3.00,3.00,82000,Australia,2001,61947.08
27596,Comparative Cost-Effectiveness Analysis of Two MSF Surgical Trauma Centers,"INTRODUCTION: There is a dearth of data on cost-effectiveness of surgical care in resource-poor countries. Doctors Without Borders (Mdecins Sans Frontires; MSF) is a nongovernmental organization (NGO) involved in the many facets of health care for underserved populations, including surgical care. METHODS: A cost-effectiveness analysis (CEA) was attempted at two of their surgical trauma hospitals: Teme Hospital in Nigeria and La Trinit Hospital in Haiti. CONCLUSION: At $172 and $223 per Disability-Adjusted Life-Year (DALY) averted, respectively, they are in line with other reported CEAs for surgical and nonsurgical activities in similar contexts.",2009-99-05410,19771466,World J Surg,Richard Gosselin,2009,/,,No,19771466,"Richard Gosselin; Andreu Maldonado; Greg Elder; Comparative Cost-Effectiveness Analysis of Two MSF Surgical Trauma Centers, World J Surg, 2009-Sep-22; ():0364-2313",DALY,Nigeria,Not Stated,"Care Delivery, Surgical",Surgical trauma hospital vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,172,United States,2008,206.76
27597,Comparative Cost-Effectiveness Analysis of Two MSF Surgical Trauma Centers,"INTRODUCTION: There is a dearth of data on cost-effectiveness of surgical care in resource-poor countries. Doctors Without Borders (Mdecins Sans Frontires; MSF) is a nongovernmental organization (NGO) involved in the many facets of health care for underserved populations, including surgical care. METHODS: A cost-effectiveness analysis (CEA) was attempted at two of their surgical trauma hospitals: Teme Hospital in Nigeria and La Trinit Hospital in Haiti. CONCLUSION: At $172 and $223 per Disability-Adjusted Life-Year (DALY) averted, respectively, they are in line with other reported CEAs for surgical and nonsurgical activities in similar contexts.",2009-99-05410,19771466,World J Surg,Richard Gosselin,2009,/,,No,19771466,"Richard Gosselin; Andreu Maldonado; Greg Elder; Comparative Cost-Effectiveness Analysis of Two MSF Surgical Trauma Centers, World J Surg, 2009-Sep-22; ():0364-2313",DALY,Haiti,Not Stated,"Care Delivery, Surgical",Surgical trauma hospital vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,223,United States,2008,268.06
27598,Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand,"OBJECTIVE: To provide input to Australian and New Zealand government decision making regarding an optimal strategy to reduce the rate of neural tube defects (NTD). DESIGN: Standard comparative health economic evaluation techniques were employed for a set of intervention options for promoting folate/folic acid consumption in women capable of or planning a pregnancy. Evidence of effectiveness was informed by the international literature and costs were derived for Australia and New Zealand. RESULTS: Population-wide campaigns to promote supplement use and mandatory fortification were the most effective at reducing NTD, at an estimated 36 and 31 fewer cases per annum respectively for Australia and New Zealand, representing an 8 % reduction in the current annual NTD rate. Population-wide and targeted approaches to increase supplement use were cost-effective, at less than $AU 12 500 per disability-adjusted life year (DALY) averted ($US 9893, pound5074), as was extending voluntary fortification. Mandatory fortification was not cost-effective for New Zealand at $AU 138 500 per DALY ($US 109 609, pound56 216), with results uncertain for Australia, given widely varying cost estimates. Promoting a folate-rich diet was least cost-effective, with benefits restricted to impact on NTD. CONCLUSIONS: Several options for reducing NTD appear to fall well within accepted societal cost-effectiveness norms. All estimates are subject to considerable uncertainty, exacerbated by possible interactions between interventions, including impacts on currently effective strategies. The Australian and New Zealand governments have decided to proceed with mandatory fortification; it is hoped they will support a rigorous evaluation which will contribute to the evidence base.",2009-99-05423,19758481,Public Health Nutr,Kim Dalziel,2009,/,1-13,No,19758481,"Kim Dalziel; Leonie Segal; Rachelle Katz; Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand, Public Health Nutr, 2009-Sep-17; ():1368-9800; 1-13",DALY,Australia,Not Stated,"Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Other",Health promotion campaign for supplement use for prevention of neural tube defects vs. Standard/Usual Care,Capable of or planning a pregnancy,64 Years,12 Years,Female,Full,", 10 year",5.00,5.00,9100,Australia,2006,8802.53
27599,Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand,"OBJECTIVE: To provide input to Australian and New Zealand government decision making regarding an optimal strategy to reduce the rate of neural tube defects (NTD). DESIGN: Standard comparative health economic evaluation techniques were employed for a set of intervention options for promoting folate/folic acid consumption in women capable of or planning a pregnancy. Evidence of effectiveness was informed by the international literature and costs were derived for Australia and New Zealand. RESULTS: Population-wide campaigns to promote supplement use and mandatory fortification were the most effective at reducing NTD, at an estimated 36 and 31 fewer cases per annum respectively for Australia and New Zealand, representing an 8 % reduction in the current annual NTD rate. Population-wide and targeted approaches to increase supplement use were cost-effective, at less than $AU 12 500 per disability-adjusted life year (DALY) averted ($US 9893, pound5074), as was extending voluntary fortification. Mandatory fortification was not cost-effective for New Zealand at $AU 138 500 per DALY ($US 109 609, pound56 216), with results uncertain for Australia, given widely varying cost estimates. Promoting a folate-rich diet was least cost-effective, with benefits restricted to impact on NTD. CONCLUSIONS: Several options for reducing NTD appear to fall well within accepted societal cost-effectiveness norms. All estimates are subject to considerable uncertainty, exacerbated by possible interactions between interventions, including impacts on currently effective strategies. The Australian and New Zealand governments have decided to proceed with mandatory fortification; it is hoped they will support a rigorous evaluation which will contribute to the evidence base.",2009-99-05423,19758481,Public Health Nutr,Kim Dalziel,2009,/,1-13,No,19758481,"Kim Dalziel; Leonie Segal; Rachelle Katz; Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand, Public Health Nutr, 2009-Sep-17; ():1368-9800; 1-13",DALY,Australia,Not Stated,"Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Other",Supplement use for minority young women for prevention of neural tube defects vs. Standard/Usual Care,Young minority groups,64 Years,12 Years,Female,Full,", 10 year",5.00,5.00,12300,Australia,2006,11897.93
27600,Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand,"OBJECTIVE: To provide input to Australian and New Zealand government decision making regarding an optimal strategy to reduce the rate of neural tube defects (NTD). DESIGN: Standard comparative health economic evaluation techniques were employed for a set of intervention options for promoting folate/folic acid consumption in women capable of or planning a pregnancy. Evidence of effectiveness was informed by the international literature and costs were derived for Australia and New Zealand. RESULTS: Population-wide campaigns to promote supplement use and mandatory fortification were the most effective at reducing NTD, at an estimated 36 and 31 fewer cases per annum respectively for Australia and New Zealand, representing an 8 % reduction in the current annual NTD rate. Population-wide and targeted approaches to increase supplement use were cost-effective, at less than $AU 12 500 per disability-adjusted life year (DALY) averted ($US 9893, pound5074), as was extending voluntary fortification. Mandatory fortification was not cost-effective for New Zealand at $AU 138 500 per DALY ($US 109 609, pound56 216), with results uncertain for Australia, given widely varying cost estimates. Promoting a folate-rich diet was least cost-effective, with benefits restricted to impact on NTD. CONCLUSIONS: Several options for reducing NTD appear to fall well within accepted societal cost-effectiveness norms. All estimates are subject to considerable uncertainty, exacerbated by possible interactions between interventions, including impacts on currently effective strategies. The Australian and New Zealand governments have decided to proceed with mandatory fortification; it is hoped they will support a rigorous evaluation which will contribute to the evidence base.",2009-99-05423,19758481,Public Health Nutr,Kim Dalziel,2009,/,1-13,No,19758481,"Kim Dalziel; Leonie Segal; Rachelle Katz; Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand, Public Health Nutr, 2009-Sep-17; ():1368-9800; 1-13",DALY,Australia,Not Stated,"Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Other",Physician advice for supplement use for prevention of neural tube defects vs. Standard/Usual Care,Capable of or planning pregnancy,64 Years,12 Years,Female,Full,", 10 year",5.00,5.00,3800,Australia,2006,3675.78
